Accord Healthcare has restarted its production of the cancer drug cisplatin, which has been in short supply in the U.S.
Accord Healthcare`s Degarelix Accord (degarelix) Receives Approval in Europe
Nov 7 (Reuters) - The U.S. Food and Drug Administration (FDA) reported on Tuesday Accord Healthcare has resumed manufacturing of methotrexate, one of the most commonly used cancer drugs, amid ongoing shortages for some cancer drugs in the United States.
LONDON and GIRONA, Spain, Aug. 4, 2023 /PRNewswire/ -- Accord Healthcare, Ltd. (Accord) and HIPRA, today announced that they have entered into an exclusive distribution agreement to commercialise HIPRA's COVID-19 vaccine in the United Kingdom (UK). The vaccine was fully developed in the European Union (EU) and consists of a bivalent adjuvanted vaccine containing a recombinant protein1. HIPRA's COVID vaccine, Bimervax®, was authorised by the UK MHRA on July 31st, 2023, as a booster for active immunisation to prevent COVID-19 in individuals 16 years of age and older who have previously received a mRNA COVID-19 vaccine1,2. The main trial compared the immune response triggered by HIPRA's vaccine with that triggered by the Comirnaty® mRNA vaccine (Pfizer/BioNTech)3. Following the results, the UK MHRA and EMA concluded that the benefits of HIPRA's vaccine outweigh its risks and recommended the granting of the marketing authorisation in the UK and the EU zone countries, respectively2,4.
Accord Healthcare`s Voriconazole Accord (voriconazole) Receives Approval in Europe
Accord Healthcare`s Dabigatran Etexilate Receives Approval in the Europe
Enforcement Report - Week of April 12, 2023
DURHAM, N.C., March 13, 2023 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Teriflunomide to its portfolio of oral medications. The drug is formulated as a film-coated tablet. Accord's Teriflunomide is therapeutically equivalent to Sanofi Genzyme's Aubagio® and is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. Accord's product is offered in a 14mg tablet and a 7mg tablet and is currently available to ship.
Enforcement Report - Week of March 8, 2023
DURHAM, N.C., Feb. 21, 2023 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Lurasidone HCL tablets to its line of generic drugs. Accord's product is AB-rated to Sunovion Pharma's Latuda® and is being offered in 20mg, 40mg, 60mg, 80mg, and 120mg doses in 30-count bottles.